Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study
Rohan Khera,Arya Aminorroaya,Lovedeep Singh Dhingra,Phyllis M Thangaraj,Aline Pedroso Camargos,Fan Bu,Xiyu Ding,Akihiko Nishimura,Tara V Anand,Faaizah Arshad,Clair Blacketer,Yi Chai,Shounak Chattopadhyay,Michael Cook,David A Dorr,Talita Duarte-Salles,Scott L DuVall,Thomas Falconer,Tina E French,Elizabeth E Hanchrow,Guneet Kaur,Wallis CY Lau,Jing Li,Kelly Li,Yuntian Liu,Yuan Lu,Kenneth KC Man,Michael E Matheny,Nestoras Mathioudakis,Jody-Ann McLeggon,Michael F McLemore,Evan Minty,Daniel R Morales,Paul Nagy,Anna Ostropolets,Andrea Pistillo,Thanh-Phuc Phan,Nicole Pratt,Carlen Reyes,Lauren Richter,Joseph Ross,Elise Ruan,Sarah L Seager,Katherine R Simon,Benjamin Viernes,Jianxiao Yang,Can Yin,Seng Chan You,Jin J Zhou,Patrick B Ryan,Martijn J Schuemie,Harlan M Krumholz,George Hripcsak,Marc A Suchard,Khera,R.,Aminorroaya,A.,Dhingra,L. S.,Thangaraj,P. M.,Pedroso Camargos,A.,Bu,F.,Ding,X.,Nishimura,A.,Anand,T. V.,Arshad,F.,Blacketer,C.,Chai,Y.,Chattopadhyay,S.,Cook,M.,Dorr,D. A.,Duarte-Salles,T.,DuVall,S. L.,Falconer,T.,French,T. E.,Hanchrow,E. E.,Kaur,G.,Lau,W. C.,Li,J.,Li,K.,Liu,Y.,Lu,Y.,Man,K. K.,Matheny,M. E.,Mathioudakis,N.,McLeggon,J.-A.,McLemore,M. F.,Minty,E.,Morales,D. R.,Nagy,P.,Ostropolets,A.,Pistillo,A.,Phan,T.-P.,Pratt,N.,Reyes,C.,Richter,L.,Ross,J.,Ruan,E.,Seager,S. L.,Simon,K. R.,Viernes,B
DOI: https://doi.org/10.1101/2024.02.05.24302354
2024-02-08
MedRxiv
Abstract:Background: SGLT2 inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1-RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, their effectiveness relative to each other and other second-line antihyperglycemic agents is unknown, without any major ongoing head-to-head trials. Methods: Across the LEGEND-T2DM network, we included ten federated international data sources, spanning 1992-2021. We identified 1,492,855 patients with T2DM and established cardiovascular disease (CVD) on metformin monotherapy who initiated one of four second-line agents (SGLT2is, GLP1-RAs, dipeptidyl peptidase 4 inhibitor [DPP4is], sulfonylureas [SUs]). We used large-scale propensity score models to conduct an active comparator, target trial emulation for pairwise comparisons. After evaluating empirical equipoise and population generalizability, we fit on-treatment Cox proportional hazard models for 3-point MACE (myocardial infarction, stroke, death) and 4-point MACE (3-point MACE + heart failure hospitalization) risk, and combined hazard ratio (HR) estimates in a random-effects meta-analysis. Findings: Across cohorts, 16.4%, 8.3%, 27.7%, and 47.6% of individuals with T2DM initiated SGLT2is, GLP1-RAs, DPP4is, and SUs, respectively. Over 5.2 million patient-years of follow-up and 489 million patient-days of time at-risk, there were 25,982 3-point MACE and 41,447 4-point MACE events. SGLT2is and GLP1-RAs were associated with a lower risk for 3-point MACE compared with DPP4is (HR 0.89 [95% CI, 0.79-1.00] and 0.83 [0.70-0.98]), and SUs (HR 0.76 [0.65-0.89] and 0.71 [0.59-0.86]). DPP4is were associated with a lower 3-point MACE risk versus SUs (HR 0.87 [0.79-0.95]). The pattern was consistent for 4-point MACE for the comparisons above. There were no significant differences between SGLT2is and GLP1-RAs for 3-point or 4-point MACE (HR 1.06 [0.96-1.17] and 1.05 [0.97-1.13]). Interpretation: In patients with T2DM and established CVD, we found comparable cardiovascular risk reduction with SGLT2is and GLP1-RAs, with both agents more effective than DPP4is, which in turn were more effective than SUs. These findings suggest that the use of GLP1-RAs and SGLT2is should be prioritized as second-line agents in those with established CVD.